시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 오피오이드 유발성 변비 치료 시장 보고서(2025년)
Opioid-Induced Constipation Treatment Global Market Report 2025
상품코드 : 1825844
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

오피오이드 유발성 변비 치료 시장 규모는 향후 몇 년 동안 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.3%로 24억 2,000만 달러로 성장할 것입니다. 예측 기간의 성장은 의약품 승인 노력의 가속화, 오피오이드 진통제 처방량 증가, 신규 치료법 연구개발비 급증, 생물학적 제제 개발 증가 등에 기인합니다. 예측 기간의 주요 동향으로는 환자 교육 및 인식 개선, 표적 치료의 등장, 비약물학적 개입, 바이오테크놀러지 혁신, 투자 증가 등이 있습니다.

향후 5년간 6.3%의 성장률 전망은 지난번 예측보다 0.4% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 관세 부과는 아일랜드와 인도에서 수입되는 말초성 mu- 오피오이드 수용체 길항제(PAMORA)의 비용을 상승시키고, 오피오이드 관련 합병증 증가와 소화기내과 처방 비용 상승으로 이어져 미국의 의료 공급망을 혼란에 빠뜨릴 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한의 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.

암 및 비암성 통증 관리를 위한 오피오이드 사용 증가는 향후 오피오이드 유발성 변비(OIC) 치료 시장의 성장을 촉진할 것으로 예상됩니다. 암성 통증은 암과 그 치료에 수반되는 통증을 말하며, 비암성 통증은 암과 무관한 증상에서 발생하는 통증을 말합니다. 이러한 통증에 대한 오피오이드 투여는 중등도에서 중증의 통증을 효과적으로 관리할 필요성에 의해 추진되고 있으며, 통증의 강도, 지속시간, 다른 치료에 대한 환자의 반응 등의 요인을 고려하여 중독 및 부작용의 위험을 최소화하면서 삶의 질을 개선하는 것을 목표로 하고 있습니다. OIC 치료는 오피오이드 사용으로 인한 변비를 완화하고, 통증 완화를 희생하지 않고 환자의 편안함, 통증 관리 요법 순응도, 전반적인 삶의 질을 개선합니다. 예를 들어, 캐나다 정부에 따르면 2025년까지 최대 830만 명의 캐나다인이 만성 통증을 경험할 것이며, 이 숫자는 2030년까지 900만 명으로 증가할 것으로 예측됩니다. 그 결과, 암 및 비암성 통증 관리에 오피오이드가 사용되면서 OIC 치료 시장 확대에 기여하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병

제34장 최근의 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSM
영문 목차

영문목차

Opioid-induced constipation (OIC) treatment encompasses diverse methods and medications employed to address constipation resulting from opioid use. The objective of these treatments is to relieve constipation symptoms while preserving the pain-relieving benefits of opioids, thus enhancing the patient's quality of life and sustaining effective pain management through a combination of pharmacological and non-pharmacological strategies.

Drug categories for treating opioid-induced constipation comprise laxatives, peripherally acting mu-opioid receptor antagonists, serotonin receptor agonists, and prostaglandins. Laxatives are remedies utilized to stimulate bowel movements and alleviate constipation by enhancing stool frequency and softening stool consistency. They can be administered via various routes, including oral and parenteral routes such as subcutaneous injection, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The opioid-induced constipation market research report is one of a series of new reports from The Business Research Company that provides opioid-induced constipation market statistics, including the opioid-induced constipation industry global market size, regional shares, competitors with opioid-induced constipation market share, detailed opioid-induced constipation market segments, market trends, and opportunities, and any further data you may need to thrive in the opioid-induced constipation industry. These opioid-induced constipation market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The opioid-induced constipation treatment market size has grown strongly in recent years. It will grow from $1.78 billion in 2024 to $1.9 billion in 2025 at a compound annual growth rate (CAGR) of 6.7%. The growth in the historic period can be attributed to expanding geriatric population, personalized OIC treatments, availability of effective OIC drugs, increasing prevalence of opioid use, and rising prevalence of gastrointestinal disorders.

The opioid-induced constipation treatment market size is expected to see strong growth in the next few years. It will grow to $2.42 billion in 2029 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to accelerated drug approval initiatives, increasing use of opioid analgesic prescriptions, surging expenditure on the R And D of novel treatments, and an increase in development of biologics. Major trends in the forecast period include patient education and awareness, the emergence of targeted therapies, non-pharmacological interventions, biotechnology innovations, and increased investment.

The forecast of 6.3% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may disrupt U.S. medical supply chains by increasing costs for peripherally acting mu-opioid receptor antagonists (PAMORAs) imported from Ireland and India, potentially leading to increased opioid-related complications and higher gastroenterology prescription expenses. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing use of opioids to manage both cancer and non-cancer pain is expected to drive the growth of the opioid-induced constipation (OIC) treatment market in the future. Cancer pain refers to the pain associated with cancer and its treatment, while non-cancer pain arises from conditions unrelated to cancer. The administration of opioids for these types of pain is driven by the need to effectively manage moderate to severe pain, taking into account factors such as pain intensity, duration, patient response to other treatments, and the goal of improving quality of life while minimizing the risks of addiction and side effects. OIC treatment helps alleviate constipation caused by opioid use, improving patient comfort, adherence to pain management regimens, and overall quality of life without sacrificing pain relief. For example, according to the Government of Canada, up to 8.3 million Canadians are expected to experience chronic pain by 2025, with this number projected to rise to 9.0 million by 2030. As a result, the growing use of opioids for managing cancer and non-cancer pain is contributing to the expansion of the OIC treatment market.

Leading companies in the opioid-induced constipation (OIC) treatment market are increasingly adopting strategic partnerships to develop innovative medicines. These partnerships enable OIC treatment companies to pool resources and expertise, enhance research and development capabilities, expand their market presence, and accelerate the commercialization of new products, thereby driving innovation and growth in the industry. For example, in November 2022, Kyowa Kirin Co. Ltd., a Japan-based biotechnology company, entered into a partnership with Grunenthal GmbH, a Germany-based pharmaceutical company. This collaboration aims to expand the growth and global availability of a portfolio of transformative pain management medicines, including treatments for opioid-induced constipation, breakthrough cancer pain, and osteoporosis, thereby improving patient outcomes worldwide.

In August 2023, Grunenthal GmbH, a pharmaceutical company headquartered in Germany, finalized a joint venture partnership with Kyowa Kirin International. This collaboration encompasses a collection of 13 brands spanning six therapeutic categories, primarily focusing on pain management, which includes treatments for breakthrough cancer pain, opioid-induced constipation, and osteoporosis. Grunenthal holds a controlling 51% stake in the joint venture, with Kyowa Kirin holding the remaining 49%. Grunenthal aims to acquire the remaining 49% ownership interest at the onset of 2026. Kyowa Kirin International, based in Japan, specializes in developing medications for opioid-induced constipation, including peripherally acting mu-opioid receptor antagonists.

Major companies operating in the opioid-induced constipation treatment market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Takeda Pharmaceutical Company Limited, Daiichi Sankyo Chemical Pharma Co. Ltd., Bausch Health Companies Inc., Boehringer Ingelheim International GmbH., Shionogi & Co. Ltd., Ono Pharmaceutical Co. Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Mundipharma International Limited, Lantheus Holdings Inc., Indivior plc, Mallinckrodt Pharmaceuticals, Collegium Pharmaceutical Inc., Ironwood Pharmaceuticals Inc., Cosmo Pharmaceuticals SA, Nektar Therapeutics, RedHill Biopharma Ltd., Theravance Biopharma Inc., Cumberland Pharmaceuticals Inc., Valinor Pharma LLC

North America was the largest region in the opioid-induced constipation treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the opioid-induced constipation treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the opioid-induced constipation treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The opioid-induced constipation treatment market includes revenues earned by entities by providing services such as dietary and lifestyle counselling, medical consultation, diagnostic and telehealth services. The market value includes the value of related goods sold by the service provider or included within the service offering. The opioid-induced constipation treatment market also includes sales of injections, tablets, syrups, lubricants, fibre supplements, enemas, suppositories and probiotics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Opioid-Induced Constipation Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on opioid-induced constipation treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for opioid-induced constipation treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The opioid-induced constipation treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Opioid-Induced Constipation Treatment Market Characteristics

3. Opioid-Induced Constipation Treatment Market Trends And Strategies

4. Opioid-Induced Constipation Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Opioid-Induced Constipation Treatment Growth Analysis And Strategic Analysis Framework

6. Opioid-Induced Constipation Treatment Market Segmentation

7. Opioid-Induced Constipation Treatment Market Regional And Country Analysis

8. Asia-Pacific Opioid-Induced Constipation Treatment Market

9. China Opioid-Induced Constipation Treatment Market

10. India Opioid-Induced Constipation Treatment Market

11. Japan Opioid-Induced Constipation Treatment Market

12. Australia Opioid-Induced Constipation Treatment Market

13. Indonesia Opioid-Induced Constipation Treatment Market

14. South Korea Opioid-Induced Constipation Treatment Market

15. Western Europe Opioid-Induced Constipation Treatment Market

16. UK Opioid-Induced Constipation Treatment Market

17. Germany Opioid-Induced Constipation Treatment Market

18. France Opioid-Induced Constipation Treatment Market

19. Italy Opioid-Induced Constipation Treatment Market

20. Spain Opioid-Induced Constipation Treatment Market

21. Eastern Europe Opioid-Induced Constipation Treatment Market

22. Russia Opioid-Induced Constipation Treatment Market

23. North America Opioid-Induced Constipation Treatment Market

24. USA Opioid-Induced Constipation Treatment Market

25. Canada Opioid-Induced Constipation Treatment Market

26. South America Opioid-Induced Constipation Treatment Market

27. Brazil Opioid-Induced Constipation Treatment Market

28. Middle East Opioid-Induced Constipation Treatment Market

29. Africa Opioid-Induced Constipation Treatment Market

30. Opioid-Induced Constipation Treatment Market Competitive Landscape And Company Profiles

31. Opioid-Induced Constipation Treatment Market Other Major And Innovative Companies

32. Global Opioid-Induced Constipation Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Opioid-Induced Constipation Treatment Market

34. Recent Developments In The Opioid-Induced Constipation Treatment Market

35. Opioid-Induced Constipation Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기